$39.30
1.52%
Nasdaq, Sep 02, 10:00 pm CET
ISIN
CA98420N1050
Symbol
XENE

Xenon Pharmaceuticals Inc. Stock price

$39.30
+6.14 18.52% 1M
+3.51 9.81% 6M
+0.10 0.26% YTD
-1.04 2.58% 1Y
+0.30 0.77% 3Y
+27.63 236.76% 5Y
+29.46 299.39% 10Y
+28.80 274.29% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
+0.59 1.52%
ISIN
CA98420N1050
Symbol
XENE
Industry

Key metrics

Basic
Market capitalization
$3.0b
Enterprise Value
$2.5b
Net debt
positive
Cash
$487.6m
Shares outstanding
76.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
398.0 | 394.8
EV/Sales
333.0 | 330.3
EV/FCF
negative
P/B
4.7
Financial Health
Equity Ratio
94.6%
Return on Equity
-31.0%
ROCE
-49.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$7.5m | $7.6m
EBITDA
$-315.5m | $-339.5m
EBIT
$-318.1m | $-348.4m
Net Income
$-278.2m | $-330.0m
Free Cash Flow
$-233.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-35.0% | -22.7%
EBIT
-33.9% | -24.7%
Net Income
-39.8% | -40.8%
Free Cash Flow
-48.9%
Margin (TTM | estimate)
Gross
-
EBITDA
-4,207.0% | -4,490.8%
EBIT
-4,241.6%
Net
-3,709.7% | -4,364.5%
Free Cash Flow
-3,106.5%
More
EPS
$-3.5
FCF per Share
$-3.0
Short interest
10.0%
Employees
322
Rev per Employee
$0.0
Show more

Is Xenon Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Xenon Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Xenon Pharmaceuticals Inc. forecast:

24x Buy
96%
1x Hold
4%

Analyst Opinions

25 Analysts have issued a Xenon Pharmaceuticals Inc. forecast:

Buy
96%
Hold
4%

Financial data from Xenon Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
7.50 7.50
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 73 73
22% 22%
973%
- Research and Development Expense 253 253
42% 42%
3,368%
-316 -316
35% 35%
-4,207%
- Depreciation and Amortization 2.59 2.59
33% 33%
35%
EBIT (Operating Income) EBIT -318 -318
34% 34%
-4,242%
Net Profit -278 -278
40% 40%
-3,710%

In millions USD.

Don't miss a Thing! We will send you all news about Xenon Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Xenon Pharmaceuticals Inc. Stock News

Neutral
GlobeNewsWire
4 days ago
VANCOUVER, British Columbia and BOSTON, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to seven new non-officer employees consisting of an aggregate of ...
Positive
Seeking Alpha
22 days ago
Xenon Pharmaceuticals is advancing azetukalner in multiple phase 3 trials for focal onset seizures, with topline X-TOLE2 data expected in early 2026. Azetukalner's mechanism and prior dose-dependent efficacy support its potential in epilepsy and neuropsychiatric indications, expanding its market opportunity. Xenon's strong cash position funds operations into 2027, with possible fundraising afte...
Neutral
Seeking Alpha
22 days ago
Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q2 2025 Earnings Conference Call August 11, 2025 4:30 PM ET Company Participants Chad Fugere - Vice President, Investor Relations Christopher John Kenney - Chief Medical Officer Darren S. Cline - Chief Commercial Officer and Member of Executive Team Ian C.
More Xenon Pharmaceuticals Inc. News

Company Profile

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Head office Canada
CEO Ian Mortimer
Employees 322
Founded 1996
Website www.xenon-pharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today